// MECHANISM_BIOLOGICAL_TARGET SYS_REF: WEE1

WEE1

ACTIVE_COMPETITORS 1 Asset

CLINICAL_EXPERIMENTS 8 Live Trials

BIOCLASS THERAPEUTIC_AREA

[01_MECHANISTIC_DESCRIPTIVE_NARRATIVE]

Wee1, a protein kinase, regulates the G2 checkpoint in response to DNA damage. Preclinical studies have elucidated the role of wee1 in DNA damage repair and the stabilization of replication forks, supporting the validity of wee1 inhibition as a viable therapeutic target in cancer.

[02_MACROMOLECULAR_3D_CONFORMATION]

Interactive structural projection resolved from the AlphaFold database engine configuration dataset mapping.

WEE1

UNIPROT: P30291

ALPHAFOLD_3D_PREDICTION

     INITIALIZING_STRUCTURAL_BIOMATRIX... 

[03_ACTIVE_COMPETITIVE_LANDSCAPE]

THERAPEUTIC ASSET

ALIAS

MAX PHASE

ZN-c3

Azenosertib

PHASE-3

[04_CROSS_REFERENCED_CLINICAL_EXPERIMENTS]

REGISTRY ID

EXPERIMENT TITLE

STAGE

EVALUATED ASSET

STATUS

NCT05128825 ↗

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors

A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

P-2

ZN-c3

recruiting